Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
about
Cytomegalovirus-induced immunopathology and its clinical consequencesRecommendations for prevention and therapy of person's exposed to B virus (Cercopithecine herpesvirus 1)Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsHuman cytomegalovirus resistance to antiviral drugsAntiviral drugs for viruses other than human immunodeficiency virusHuman herpesvirus 6Polyradiculopathy and Gastroparesis due to Cytomegalovirus Infection in AIDS: A Case Report and Review of LiteratureCytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationDefinitions of cytomegalovirus infection and disease in transplant recipientsAntiviral drug resistance: mechanisms and clinical implicationsValganciclovir results in improved oral absorption of ganciclovir in liver transplant recipientsAcyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent IndividualsInfection in Organ Transplantation.Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem.Guanosine analogues as anti-herpesvirus agents.A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.Cytomegalovirus: pathogen, paradigm, and puzzleValganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.Antiviral selection in the management of acute retinal necrosis.Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal functionNew strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsA Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients.Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients.Cadaver donor screening for infectious agents in solid organ transplantation.Prevention of cytomegalovirus disease in recipients of solid-organ transplants.Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation.Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.Human herpesviruses 6 and 7 in solid organ transplant recipients.Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts.Prophylaxis and treatment of gastrointestinal complications following transplantation.Valacyclovir for the treatment of genital herpes.Herpesvirus infections in organ transplant recipientsHuman cytomegalovirus terminase as a target for antiviral chemotherapy.
P2860
Q21195897-CD53AE95-9B86-461F-A97C-7B4B51992782Q23914574-6D974BCC-38C0-43C3-ABA1-435525D8009CQ24200697-F3E9A00F-256D-46DC-838D-0B61BE34C0AEQ24200991-D183E02A-03A0-4150-B1B6-7BE51BE91F6AQ24243124-E8383F6A-35FB-4F3A-9E7B-217CDF717C5AQ24244606-D5C97838-81B8-4454-BE15-E39849DD87F4Q24556634-C36FF30D-BA60-4636-927E-5BEBE4A2CDF6Q24635330-EEF95D0F-90C9-4F34-8CBF-F67DA88E7EEDQ24683663-C5D51D49-456F-4A82-9FBA-1FF82BD2CC08Q26778313-815F37F7-DE06-42FE-8593-01E750D8860AQ28082017-6E698E08-D1D8-4EF1-8098-FFB6537BC24BQ28085440-A321B40F-AD95-4D0A-8AC4-AC3833A086D0Q28210268-ABD3ACC9-3A48-4256-AEB7-623EE2C1D6C1Q28282376-6A8A050E-231E-4EB7-B1F8-DFBC4F7BA85EQ28344757-8D9AD59B-4176-4462-8262-35F91C4B7A1BQ28546851-210102EC-B9AC-432C-B116-04A129DD8C9EQ30238810-E6B3F7A7-EFC5-4A26-A5ED-B5EA2E26ADB8Q30453768-CBF1AD9C-5EAE-42A9-ADC5-FEF8D18CF366Q30583015-BEEF0A76-2128-4835-AFDC-8F2A06D5699CQ31996846-D784A0D2-EC98-430F-9675-8AE6CD773C16Q33345650-9957DE93-A3A1-49FD-8714-AC39E8B543C1Q33351523-32B67849-5C4D-43A1-B8B6-284E204722F7Q33363887-B8BE5DF2-CC5D-4736-9C81-BF161B334CD3Q33644146-42D2FECC-02EC-4B7E-8CED-F5EB37F69D80Q33676105-DACCC752-5EA1-45CA-AF67-42216A7D5F7BQ33812425-AFA10647-83F2-474C-B845-5DACB5B1C889Q33871850-BC9A57EF-2C1E-4C3E-B651-E6FA6BB79774Q33969461-CC2E4CCE-BA3A-472C-8000-CDCC0718BFE4Q34052592-FD445742-B728-47BB-825E-96EFF89A386AQ34142019-9E576908-8399-41B3-B60E-E7CB4CEDF6FBQ34191785-DF809617-0D06-4F38-8022-394DFCC699FCQ34191791-C4C3C4F2-40B2-41ED-8AAA-A6C1B2A22417Q34219626-51A9F201-94CE-4BC9-8E4B-CF1F04ACB1EDQ34294806-1B6C8D59-2E55-4FF1-8B2B-231E7870B408Q34373532-365DAEB6-1EC3-4A03-9976-6E1E79D4647BQ34481742-53D193D8-EA8C-4002-9930-2D390C3DC638Q34485493-CD4B9B1E-D64B-4E4E-A4AB-F334CF76D550Q34568338-62041832-233A-4251-B32C-606506121998Q34579836-10538C41-A81C-4B7B-AFCF-3A6B21A7172DQ34580776-8210DA40-48F5-476C-8A0A-1E6E06EF80D7
P2860
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Valacyclovir for the preventio ...... s Transplantation Study Group.
@en
Valacyclovir for the preventio ...... s Transplantation Study Group.
@nl
type
label
Valacyclovir for the preventio ...... s Transplantation Study Group.
@en
Valacyclovir for the preventio ...... s Transplantation Study Group.
@nl
prefLabel
Valacyclovir for the preventio ...... s Transplantation Study Group.
@en
Valacyclovir for the preventio ...... s Transplantation Study Group.
@nl
P2093
P1476
Valacyclovir for the preventio ...... s Transplantation Study Group.
@en
P2093
Brennan PJ
Keating MR
Legendre CM
Neumayer HH
P304
P356
10.1056/NEJM199905133401903
P407
P577
1999-05-01T00:00:00Z